Current Landscape of Immunotherapy for Advanced Sarcoma.

Area of Science:

• Oncology
• Immunology
• Cancer Research

Background:

• Sarcoma subtypes exhibit significant heterogeneity in biological behavior and tumor microenvironment.
• This heterogeneity influences the efficacy of various immunotherapeutic strategies.
• Understanding these differences is crucial for optimizing treatment outcomes.

Purpose of the Study:

• To review the current landscape of immunotherapy for sarcoma.
• To highlight the differential responses of sarcoma subtypes to immunotherapy.
• To discuss emerging therapeutic modalities and biomarkers.

Main Methods:

• Literature review of preclinical and clinical studies on sarcoma immunotherapy.
• Analysis of data on immunogenicity and response rates across different sarcoma subtypes.
• Evaluation of combination strategies and novel cell-based therapies.

Main Results:

• Alveolar soft-part sarcoma, synovial sarcoma, and undifferentiated pleomorphic sarcoma demonstrate higher immunogenicity and improved responses to checkpoint inhibitors.
• Combination strategies involving immunotherapy with chemotherapy and/or tyrosine-kinase inhibitors show superiority over single-agent treatments.
• Therapeutic vaccines, engineered T-cell receptors (TCRs), CAR-T cells, and tumor-infiltrating lymphocyte (TIL) therapy represent emerging immunotherapy options.

Conclusions:

• Immunotherapy efficacy in sarcoma is subtype-dependent.
• Combination approaches and advanced cell therapies hold significant promise for advanced sarcomas.
• Further research into prognostic and predictive biomarkers, such as tumor lymphocytic infiltration, is essential.